You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Claims for Patent: 12,220,401


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,220,401
Title:Compounds useful as kinase inhibitors
Abstract:This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Inventor(s):Nicolas Guisot
Assignee: Loxo Oncology Inc
Application Number:US18/362,249
Patent Claims: 1. A compound of the formula: wherein * indicates a chiral center, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition, wherein the pharmaceutical composition comprises a compound of the formula: wherein * indicates a chiral center, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

3. A method of treating a condition which is modulated by BTK in a patient in need thereof comprising administering to the patient a compound of the formula: wherein * indicates a chiral center, or a pharmaceutically acceptable salt thereof.

4. The method according to claim 3 wherein the condition modulated by BTK is cancer, lymphoma, leukemia, autoimmune diseases, inflammatory disorders, heteroimmune conditions, or fibrosis.

5. The method according to claim 4 wherein the condition modulated by BTK is selected from B-cell malignancy, B-cell lymphoma, diffuse large B cell lymphoma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, ABC-DLBCL, mantle cell lymphoma, follicular lymphoma, hairy cell leukemia, B-cell non-Hodgkin lymphoma, Waldenstrom's macroglobulinemia, multiple myeloma, bone cancer, bone metastasis, arthritis, multiple sclerosis, osteoporosis, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, Sjögren's syndrome, and lupus.

6. The method according to claim 5 wherein the condition modulated by BTK is selected from arthritis, multiple sclerosis, osteoporosis, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, and lupus.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.